Postoperative pulmonary toxicity associated with mitomycin-C therapy.
As more patients survive cancer, and as more sophisticated multidrug antineoplastic protocols are developed, the chances of an anesthesiologist's coming into contact with patients who have been treated with such protocols are increasing. The anesthesiologist who must administer anesthesia to a patient who has had chemotherapy must be cognizant of the particular antineoplastic agents that have the potential for producing occult pulmonary dysfunction. Anesthetic management of these cases must be carefully planned and titrated to prevent further lung injury.
Thompson
C C
CC
Department of Anesthesiology, Medical University of South Carolina, Charleston 29425.
Bailey
M K
MK
Conroy
J M
JM
Bromley
H R
HR
D000328:Adult; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D016685:Mitomycin / Q000009:adverse effects* / Q000627:therapeutic use; D011183:Postoperative Complications / Q000139:chemically induced*; D011658:Pulmonary Fibrosis / Q000139:chemically induced; D012131:Respiratory Insufficiency / Q000139:chemically induced*
D016685:Mitomycin